Jun 25, 2020

New Collaborative Publication from Multiple MBP Researchers

Graphical Abstract

Image of a Graphical Abstract

MBP scientists Dr. Annie Huang, Dr. Uri Tabori, Dr. Michael Taylor, Dr. Vijay Ramaswamy and several research associates have collaborated on a newly-published Cell article entitled ‘Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma.

Article Abstract
‘Over the past decade, wingless-activated (WNT) medulloblastoma has been identified as a candidate for therapy de-escalation based on excellent survival; however, a paucity of relapses has precluded additional analyses of markers of relapse. To address this gap in knowledge, an international cohort of 93 molecularly confirmed WNT MB was assembled, where 5-year progression-free survival is 0.84 (95%, 0.763–0.925) with 15 relapsed individuals identified. Maintenance chemotherapy is identified as a strong predictor of relapse, with individuals receiving high doses of cyclophosphamide or ifosphamide having only one very late molecularly confirmed relapse (p = 0.032). The anatomical location of recurrence is metastatic in 12 of 15 relapses, with 8 of 12 metastatic relapses in the lateral ventricles. Maintenance chemotherapy, specifically cumulative cyclophosphamide doses, is a significant predictor of relapse across WNT MB. Future efforts to de-escalate therapy need to carefully consider not only the radiation dose but also the chemotherapy regimen and the propensity for metastatic relapses.’

View the article on the Cell website.